Company Overview of Renovar, Inc.
Renovar, Inc. engages in the discovery and development of diagnostic tests based on a portfolio of protein biomarkers for kidney disease and transplant monitoring. It provides a portfolio of protein biomarkers that indicate kidney injury using its urinary immunoassay platform; and CFSE Flow Kit that is used for tracking eight generations of cell proliferation in-vivo and in-vitro for mouse and human cells by flow cytometry. The company also offers custom assays and study services to support research activities, including biomarker selection and assay panel development, study design, data analysis, and samples testing. Renovar, Inc. was founded in 1999 and is headquartered in Appleton, Wiscon...
200 East Washington
Appleton, WI 54911
Founded in 1999
Key Executives for Renovar, Inc.
Chief Executive Officer, President and Director
Co-Founder, Chairman of the Board and Chief Scientific Officer
Co-Founder, Vice President and Director
Compensation as of Fiscal Year 2016.
Renovar, Inc. Key Developments
ViveBio Enters Licensing Agreement with Renovar for Novel Urine Based Biomarker Technologies Covering Kidney Disease and Transplant Monitoring
Feb 10 15
ViveBio, LLC announced that it has signed a worldwide exclusive licensing agreement with Renovar, Inc. for urine based biomarkers to predict and monitor kidney diseases as well as rejection in transplant recipients. Based upon unique inflammatory protein signatures found in the urine of diseased or injured kidney's, the Renovar technology can be used to assess the health of a patients kidney's, guide therapeutic decision making and help stratify patients by risk for developing acute rejection. Based upon an NIH sponsored, prospective, multicenter study of 280 kidney transplant recipients researchers evaluated the urinary levels of nine messenger RNAs and two proteins which are known to be associated with kidney transplant rejection. They identified Monokine induced by interferon-gamma (MIG) messenger RNA (mRNA) and MIG protein as the clinically significant biomarkers. After further testing, the researchers found that MIG protein was better at ruling out rejection than any of the mRNA's tested. It was also capable of identifying patients likely to have stable long-term kidney function and identify those patients who were unlikely to experience rejection or loss of kidney function over the next 18 months. The investigators noted that urinary MIG protein levels began to increase up to 30 days before clinical signs of kidney injury.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries